These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 16527535)

  • 1. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
    Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
    J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors.
    Buzon MJ; Erkizia I; Pou C; Minuesa G; Puertas MC; Esteve A; Castello A; Santos JR; Prado JG; Izquierdo-Useros N; Pattery T; Van Houtte M; Carrasco L; Clotet B; Ruiz L; Martinez-Picado J
    J Antimicrob Chemother; 2012 Jan; 67(1):32-8. PubMed ID: 21994909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
    J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.
    Blumenzweig I; Baraz L; Friedler A; Danielson UH; Gilon C; Steinitz M; Kotler M
    Biochem Biophys Res Commun; 2002 Apr; 292(4):832-40. PubMed ID: 11944889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro synthesis of enzymatically active HIV-1 protease for rapid phenotypic resistance profiling.
    Hoffmann D; Buchberger B; Nemetz C
    J Clin Virol; 2005 Apr; 32(4):294-9. PubMed ID: 15780808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M.
    Ode H; Neya S; Hata M; Sugiura W; Hoshino T
    J Am Chem Soc; 2006 Jun; 128(24):7887-95. PubMed ID: 16771502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
    J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H; Schön A; Freire E
    Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
    Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
    Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.
    Ermolieff J; Lin X; Tang J
    Biochemistry; 1997 Oct; 36(40):12364-70. PubMed ID: 9315877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations.
    Saen-oon S; Aruksakunwong O; Wittayanarakul K; Sompornpisut P; Hannongbua S
    J Mol Graph Model; 2007 Nov; 26(4):720-7. PubMed ID: 17543558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
    Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
    Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.
    Bartonová V; Král V; Sieglová I; Brynda J; Fábry M; Horejsí M; Kozísek M; Sasková KG; Konvalinka J; Sedlácek J; Rezácová P
    Antiviral Res; 2008 Jun; 78(3):275-7. PubMed ID: 18329737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins.
    Cherry E; Liang C; Rong L; Quan Y; Inouye P; Li X; Morin N; Kotler M; Wainberg MA
    J Mol Biol; 1998 Nov; 284(1):43-56. PubMed ID: 9811541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-2 Protease resistance defined in yeast cells.
    M'Barek NB; Audoly G; Raoult D; Gluschankof P
    Retrovirology; 2006 Sep; 3():58. PubMed ID: 16956392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
    Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
    Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.
    Menzo S; Monachetti A; Balotta C; Corvasce S; Rusconi S; Paolucci S; Baldanti F; Bagnarelli P; Clementi M
    AIDS; 2003 Mar; 17(5):663-71. PubMed ID: 12646788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication.
    Cherry E; Morin N; Wainberg MA
    AIDS; 1998 Jun; 12(9):967-75. PubMed ID: 9662192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteochemometric modeling of drug resistance over the mutational space for multiple HIV protease variants and multiple protease inhibitors.
    Lapins M; Wikberg JE
    J Chem Inf Model; 2009 May; 49(5):1202-10. PubMed ID: 19391634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.